Qing-quan Zu

No. 300 Guangzhou Road
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Dual-energy computed tomography venography parameters as potential indicators for pulmonary embolism in deep vein thrombosis.

Dual-energy computed tomography venography parameters as potential indicators for pulmonary embolism in deep vein thrombosis.

Journal: Journal of thoracic disease

Published: January 26, 2026

Comparison of short-term changes in right ventricular function after catheter-directed thrombolysis-based therapy vs. anticoagulation alone in acute intermediate-risk pulmonary embolism.

Comparison of short-term changes in right ventricular function after catheter-directed thrombolysis-based therapy vs. anticoagulation alone in acute intermediate-risk pulmonary embolism.

Journal: Journal of thoracic disease

Published: November 26, 2025

The characteristics of upper lobe-origin hemoptysis: analysis based on 31 patients.

The characteristics of upper lobe-origin hemoptysis: analysis based on 31 patients.

Journal: Journal of thoracic disease

Published: September 11, 2025

Pre-emptive Oxycodone versus Sufentanil for Acute and Delayed Pain after Transcatheter Arterial Chemoembolization: A Randomized Controlled Trial with Inflammatory Biomarker Analysis.

Pre-emptive Oxycodone versus Sufentanil for Acute and Delayed Pain after Transcatheter Arterial Chemoembolization: A Randomized Controlled Trial with Inflammatory Biomarker Analysis.

Journal: Journal of vascular and interventional radiology : JVIR

Published: June 17, 2025

MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC.

MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC.

Journal: Academic radiology

Published: April 01, 2025

Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study.

Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study.

Journal: Hepatobiliary & pancreatic diseases international : HBPD INT

Published: December 05, 2024

Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors.

Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors.

Journal: Journal of hepatocellular carcinoma

Published: November 13, 2024

Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.

Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.

Journal: Annals of medicine

Published: November 01, 2024

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study.

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study.

Journal: Journal of hepatocellular carcinoma

Published: June 11, 2024

Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.

Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.

Journal: Annals of medicine

Published: May 31, 2022

Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.

Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.

Journal: Journal of hepatocellular carcinoma

Published: May 03, 2022

Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.

Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.

Journal: Canadian journal of gastroenterology & hepatology

Published: March 05, 2022

Showing 1-12 of 45

Last Updated: 09/26/2026